PURPOSE: We compared our institutional experience using 3D conformal radiation therapy (3DCRT) vs. IMRT (intensity-modulated radiation therapy) for anal cancer. METHODS: We performed a single-institution retrospective review of all patients with squamous cell carcinoma anal cancer treated from September 2000 through September 2011, using definitive chemoradiation with curative intent. RESULTS: This study included 89 consecutive patients (37 3DCRT, 52 IMRT). Median follow-up for all patients, IMRT patients alone, and CRT patients alone was 26.5 months (range, 3.5-133.6), 20 months (range, 3.5-125.5), and 61.9 months (range, 7.6-133.6), respectively. Three-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and colostomy-free survival (CFS) were 91.1%, 82.3%, 90.8%, and 91.3% in the IMRT cohort and 86.1%, 72.5%, 91.9%, and 93.7% in the 3DCRT group (all P > .1). More patients in the 3DCRT group required a treatment break (11 vs. 4; P = .006), although the difference in median treatment break duration was not significant (12.2 vs. 8.0 days; P = .35). Survival did not differ based on whether a treatment break was needed (all P > .1). Acute grade ≥3 nonhematologic toxicity was decreased in the IMRT cohort (21.1 vs. 59.5%; P < .0001). Acute grade ≥3 skin toxicity was worse in the 3DCRT group (P < .0001), whereas an improvement in late grade ≥3 gastrointestinal (GI) toxicity was observed in the IMRT patients (P = .012). CONCLUSIONS: This study is the largest thus far to compare 3DCRT and IMRT for definitive treatment of anal cancer. Although long-term outcomes did not significantly differ based on RT technique, a marked decrease in adverse effects and the need for a treatment break was achieved with IMRT.
PURPOSE: We compared our institutional experience using 3D conformal radiation therapy (3DCRT) vs. IMRT (intensity-modulated radiation therapy) for anal cancer. METHODS: We performed a single-institution retrospective review of all patients with squamous cell carcinoma anal cancer treated from September 2000 through September 2011, using definitive chemoradiation with curative intent. RESULTS: This study included 89 consecutive patients (37 3DCRT, 52 IMRT). Median follow-up for all patients, IMRT patients alone, and CRT patients alone was 26.5 months (range, 3.5-133.6), 20 months (range, 3.5-125.5), and 61.9 months (range, 7.6-133.6), respectively. Three-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and colostomy-free survival (CFS) were 91.1%, 82.3%, 90.8%, and 91.3% in the IMRT cohort and 86.1%, 72.5%, 91.9%, and 93.7% in the 3DCRT group (all P > .1). More patients in the 3DCRT group required a treatment break (11 vs. 4; P = .006), although the difference in median treatment break duration was not significant (12.2 vs. 8.0 days; P = .35). Survival did not differ based on whether a treatment break was needed (all P > .1). Acute grade ≥3 nonhematologic toxicity was decreased in the IMRT cohort (21.1 vs. 59.5%; P < .0001). Acute grade ≥3 skin toxicity was worse in the 3DCRT group (P < .0001), whereas an improvement in late grade ≥3 gastrointestinal (GI) toxicity was observed in the IMRT patients (P = .012). CONCLUSIONS: This study is the largest thus far to compare 3DCRT and IMRT for definitive treatment of anal cancer. Although long-term outcomes did not significantly differ based on RT technique, a marked decrease in adverse effects and the need for a treatment break was achieved with IMRT.
Authors: Yi-Jen Chen; An Liu; Peter T Tsai; Nayana L Vora; Richard D Pezner; Timothy E Schultheiss; Jeffrey Y C Wong Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-01 Impact factor: 7.038
Authors: Jose G Bazan; Wendy Hara; Annie Hsu; Pamela A Kunz; James Ford; George A Fisher; Mark L Welton; Andrew Shelton; Daniel S Kapp; Albert C Koong; Karyn A Goodman; Daniel T Chang Journal: Cancer Date: 2011-02-01 Impact factor: 6.860
Authors: H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Michael T Milano; Ashesh B Jani; Karl J Farrey; Carla Rash; Ruth Heimann; Steven J Chmura Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Edgar Ben-Josef; Jennifer Moughan; Jaffer A Ajani; Marshall Flam; Leonard Gunderson; JonDavid Pollock; Robert Myerson; Rani Anne; Seth A Rosenthal; Christopher Willett Journal: J Clin Oncol Date: 2010-10-18 Impact factor: 44.544
Authors: Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Ramin Roohipour; Sujata Patil; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; José G Guillem; Philip B Paty; Martin R Weiser; Heather B Neuman; Jinru Shia; Deborah Schrag; Larissa K F Temple Journal: Dis Colon Rectum Date: 2008-01-08 Impact factor: 4.585
Authors: Steven H Lin; Ning Zhang; Joy Godby; Jingya Wang; Gary D Marsh; Zhongxing Liao; Ritsuko Komaki; Linus Ho; Wayne L Hofstetter; Stephen G Swisher; Reza J Mehran; Thomas A Buchholz; Linda S Elting; Sharon H Giordano Journal: Cancer Date: 2015-12-30 Impact factor: 6.860